Redenlab supporting Larimar Therapeutics in Phase 1 SAD Clinical Trial

Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

Click here to learn more.

Tags: ,

Related Post

Redenlab contributes to position paper on advancing digital healthtechnologies for frontotemporal degeneration

  • Posted on 15 May, 2025
    MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap for the...
    Read more

    Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research

    • Posted on 11 December, 2024
      MEDIA RELEASE Melbourne - December 2024 – Redenlab, a leader in innovative healthcare solutions, has partnered with the Queensland Institute of Medical...
      Read more

      Expanding the phenotype of Kleefstra syndrome: speech, language and cognition in 103 individuals

      • Posted on 31 March, 2024
        Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
        Read more